证券日报网讯德展健康（000813）9月29日在互动平台回答投资者提问时表示，WYY注射液脑卒中适应 症IND申报相关实验基本完成，预计下半年提交临床试验申请。 ...

格隆汇9月29日丨德展健康(000813.SZ)在投资者互动平台表示，WYY注射液脑卒中适应症IND申报相关 实验基本完成，预计下半年提交临床试验申请。 ...

Group 1 - The core point of the news is that Shanghai Yueye has successfully auctioned and transferred all shares of Dezhan Health, eliminating a long-standing potential selling pressure in the market [1] - The shareholding structure of Dezhan Health has become clearer, with the largest shareholder being Xinjiang Kaidi Investment Co., Ltd. holding 19.54% and the second largest being Merrill Holdings Group Ltd. holding 8.87% [1] - The actual controller of the company is the State-owned Assets Supervision and Administration Commission of the People's Government of Xinjiang Uygur Autonomous Region [1] Group 2 - Dezhan Health is a leading domestic company engaged in the research, production, and sales of cardiovascular drugs [2] - The company is focusing on deepening its technology innovation strategy and expanding its business layout towards "pharmaceuticals + medical + health" [2] - Dezhan Health has established a collaboration with the Chinese Academy of Engineering and is actively promoting various research projects with renowned institutions [2] Group 3 - The company has made progress in its product pipeline, with IND application for WYY injection for stroke indications expected to be submitted in the second half of the year [2] - The company plans to submit a registration application for CBD raw materials to the FDA in the second half of the year, with production expected to commence in the second half of 2025 [2] - The company is also involved in clinical trials for various cancer-related products, including VGX-3100 for cervical precancerous lesions and new drug exploration for COPD and pancreatic cancer [2]